Atualmente, nota-se um crescimento na fabricação de produtos utilizando moldes e matrizes contendo formas geométricas complexas. No entanto, a fabricação destes ferramentais onde se emprega, principalmente, operações de fresamento, não tem acompanhado esta evolução com a mesma velocidade. O advento dos sistemas CAD/CAM, máquinas CNC e da tecnologia de usinagem em altas velocidades (HSC) influenciaram positivamente a fabricação de superfícies complexas. Contudo, nota-se ainda ineficiências neste processo produtivo. A qualidade superficial após as operações de usinagem ainda não é suficiente para que estes ferramentais entrem diretamente na linha de produção. Assim, operações manuais de acabamento são exigidas, elevando o tempo e custo de produção, comprometendo a qualidade dimensional. Com a finalidade de aprimorar a fabricação de moldes e matrizes, este trabalho apresenta uma revisão bibliográfica sobre a usinagem HSC; um estudo sobre a força de usinagem para o fresamento de formas complexas e uma análise sobre a metodologia utilizada por sistemas CAD/CAM e CNC para gerar e interpretar programas NC que contenham movimentações complexas de ferramenta. Análises práticas foram realizadas em um centro de usinagem HSC, e os resultados indicam que as limitações tecnológicas atuais na cadeia CAD/CAM/CNC limitam a usinagem de formas complexas com altas velocidades, reduzindo a velocidade de avanço programada e que as características intrínsecas deste processo de remoção de material demonstrou ser bastante complexo, acarretando em constantes alterações na força de usinagem / In recent years the number of products containing free-form shapes produced by dies and molds have been growing noticeably. However, the milling process used to manufacture those dies and molds does not meet their requirements. The arrival of the CAD/CAM systems and the High Speed Cutting Technology (HSC) helps to improve this manufacturing process. Although to obtain the surface quality needed to meet the dies and molds requirements, a hand finishing still requires. It involves time, money and decrease the product quality. Technological limitations in the CAD/CAM/CNC chain limit the feed rate when milling free-form shape. It also has a negative effect on the surface roughness. Besides, this kind of milling still lacks scientific knowledge of the cutting process. With the aim to support the dies and moulds fabrication, this work presents an overview about HSC Technology; the cutting forces in a non-planar milling; the cutting tool deflection; a detailed description of the process chain involving the CAD/CAM/CNC systems and the methodologies used by those systems to generate and accomplish free-free tool-paths. Free-form milling experiments applying the HSC Technology were made to study the behavior of this process, and the outcomes are presented

Ce travail concerne des hémopathies myéloïdes malignes appelés Néoplasmes Myéloprolifératifs (NMP) qui incluent les Polyglobulies de Vaquez (PV), les Thrombocythémies Essentielles (TE) et les Myélofibroses Primaires (MFP). Ces maladies résultent de la transformation d’une cellule souche hématopoïétique (CSH) avec hyperprolifération mais sans blocage de différentiation. Leur défaut moléculaire le plus fréquent est la mutation JAK2V617F résultant dans l’activation de la signalisation des récepteurs aux cytokines utilisant JAK2. Au cours de ce travail, nous avons développé un modèle murin « Knock-In » (KI) constitutif et conditionnel pour la mutation JAK2V617F. Ces animaux développent une maladie mimant la PV humaine évoluant vers la MF secondaire. Ces animaux présentent augmentation en fonction de l’âge du nombre de cellules immatures (phénotypes Lin-, LSK et SLAM: LSK/CD48-/CD150+). Dans un système compétitifs in vivo nous montrons que les cellules KI ont un avantage prolifératif dés le stade CSH et qu'un faible nombre de CSH peuvent déclencher la maladie. Ces résultats suggèrent que la mutation JAK2V617F seule est suffisante pour (1) le phénotype et (2) l'émergence de ces maladies. Nous avons aussi testé l'effet de l'interféron-a (IFNa) sur le développement des NMP en utilisant ces souris JAK2V617F KI. Nous montrons que l'IFNa traite le phénotype de la maladie en bloquant la propagation des cellules KI dés le stade immature avec éradication des cellules souches néoplasiques, entraînant comme chez certains patients PV une rémission hématologique et aussi moléculaire. Enfin, en combinant l’analyse quantitative de l’haplotype 46/1 et de la mutation JAK2V617F sur les cellules sanguines nous développons une nouvelle méthode prédictive de la fréquence des clones hétérozygotes et homozygotes JAK2V617F chez les patients PV. Cette étude suggère que l'IFNa cible préférentiellement le clone homozygote JAK2V617F et que sa réponse est fonction de l’intensité de la signalisation JAK2. / This work concerns malignant myeloid hemopathies called classical BCR-ABL-negative Myeloproliferative Neoplasms (MPN) and include Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). They result from the transformation of a multipotent hematopoietic stem cell (HSC) with hyperproliferation but no blockade of differentiation. The most common molecular defect is the acquired point mutation JAK2V617F resulting into the activation of the cytokine receptor/JAK2 pathway. We have developed a mouse constitutive and a conditional JAK2V617F knock-in (KI) mouse models. These animals developed a disease mimicking human PV evolving into secondary MF. They also displayed an age dependent increase in the total numbers of early hematopoietic cells (phenotype LK, LSK and SLAM: LSK/CD48-/CD150+). Using In vivo competitive repopulation assays we demonstrated that cells from KI origin outcompeted their WT counterparts and that a low number of JAK2V617F KI SLAM cells propagates the disease. These results show that the sole JAK2V617F mutation, without any additional mutations, is sufficient for disease phenotype and emergence. Using this KI mouse model, we tested the effect of interferon-a (IFNa) treatment on MPN development. We found that IFNa treats the disease phenotype by blocking the propagation of early JAK2V617F cells and eradicates disease-initiating cells, showing that IFNα could cure the disease in mice, as shown in some PV patients. Finally, we developed a new method combining the measurement of 46/1 SNPs and JAK2V617F allele burdens in blood predicting the frequency of normal, heterozygous and homozygous JAK2V617F clones in PV patients. This study suggested that IFNa preferentially targets the homozygous JAK2V617F clone in PV patients suggesting a link between the levels of JAK2 signaling and the success of the IFNa response.

Les propriétés centrales des cellules souches sont la pluripotence et la capacité d'auto-renouvellement. Les cellules souches hématopoïétiques (CSHs) sont dotées de ces caractéristiques qui leur permettent de générer toutes les cellules du compartiment hématopoïétique, tout en maintenant en parallèle leur compartiment. Nous menons des approches visant à amplifier ex vivo les CSHs en les activant par HOXB4 exogène (CSHs humaines) ou via la signalisation Notch/DLL-4 (CSHs murines). Or deux analyses transcriptomiques indépendantes de ces deux modes d'activation ont de manière étonnante convergé sur une augmentation de l'expression de deux gènes jamais identifiés auparavant comme étant impliqués dans le maintien des CSHs : Pumilio1 (Pum1) et Pumilio2 (Pum2). Pum1 et Pum2 sont des régulateurs post-transcriptionnels appartenant à la famille Pumilio-FBF (PUF) des protéines liant l'ARN. Bien qu'il ait été établi que le rôle princeps de ces protéines PUF est de soutenir la prolifération des cellules souches chez les Invertébrés, jusqu'à présent on ne sait rien du rôle de Pum1 et Pum2 dans les CSH humaines et murines.Pour toutes ces raisons, nous avons étudié le rôle et les mécanismes d'action de Pum1 et Pum2 dans les CSH murines et humaines en utilisant l'interférence ARN (ARNi). L'invalidation de Pum1 ou de Pum2 dans les CSHs murines conduit à une réduction de l'expansion et du potentiel clonogénique ex vivo, associée à une apoptose accrue et l'arrêt du cycle cellulaire en phase G0/G1. L'invalidation concomitante de Pum1 et Pum2 majore ces effets ce qui suggère un effet coopératif entre les deux protéines. L'expansion et le potentiel clonogénique des CSH invalidées pour Pum1 sont restaurés suite à l'expression forcée de Pum1 (insensible au shRNA utilisé), validant ainsi la spécificité de nos shRNAs. Par contre la surexpression de Pum1 dans les CSHs invalidées pour Pum2 ne restaure pas leurs fonctions, soulignant le rôle non redondant de chaque protéine. En outre, lorsque les CSHs invalidées pour Pum1 ou Pum2 sont inoculées à des souris irradiées létalement de suivre le potentiel hématopoïétique à long terme, seules quelques rares cellules de la moelle osseuse issues des CSH KD pour Pum1 ou Pum2 sont mises en évidence après 4 mois de reconstitution, contrairement aux CSH contrôles. Des résultats identiques ont été obtenus en invalidant Pum1 ou Pum2 dans les CSH humaines.En conclusion, nos résultats démontrent l'implication des facteurs Pumilio dans le maintien du potentiel souche, l'expansion et la survie des CSHs murines et humaines. L'identification des facteurs Pumilio et de leurs cibles comme nouveaux régulateurs des CSHs permettra d'envisager de nouveaux outils en vue de perspectives thérapeutiques. / The central properties of stem cells are the pluripotency and the capacity of self-renewal. Hematopoietic stem cells (HSCs) posses such common features that allows them to generate all the cells of the hematopoietic compartments, maintaining in the same time the HSC pool. We develop approaches focused on ex vivo HSC expansion through activation by exogenous HOXB4 (human HSCs) or Notch/Dll-4 ligand (murine HSCs). Two independent transcriptomic analyses surprisingly converged toward an increased expression of two genes never identified sofar as crucial for HSC functions: Pumilio1 (Pum1) and Pumilio2 (Pum2). Pum1 and Pum2 are posttranscriptional regulators belonging to the Pumilio-FBF (PUF) family of RNA-binding proteins. Although it was established that the primordial role of PUF proteins is to sustain mitotic proliferation of stem cells in Invertebrates, so far nothing is known about the role of Pum1 and Pum2 in human and murine HSCs.For these reasons, we have investigated the roles and mechanisms of action of Pum1 and Pum2 in murine and human HSCs through shRNA strategy. Pum1 and Pum2 knockdown (KD) in murine HSCs led to a decreased HSC expansion and clonogenic potential ex vivo, associated with an increased apoptosis and a cell cycle arrest in G0/G1 phase. KD of both Pum1 and Pum2 enhanced these effects, suggesting a cooperative effect. Expansion and clonogenic potential of KD Pum1 HSCs were rescued by enforced expression of Pum1 (insensitive to our shRNA), thus validating the specificity of our shRNA. Enforced expression of Pum1 could not rescue the functions of Pum2 KD HSCs, highlighting the non-redundant role of these proteins. Furthermore, when Pum1 or Pum2 KD HSCs were inoculated into lethally irradiated mice to follow the long-term hematopoietic potential, only rare bone marrow cells derived from Pum1 and Pum2 KD HSCs were evidenced after 4 months, contrary to control HSCs. Identical results were obtained with human Pum1 or Pum2 KD HSCs.In conclusion, our results demonstrate the involvement of Pumilio factors in stemness maintenance, expansion and survival of murine and human HSCs. Identification of Pumilio factors and their targets as new regulators of HSCs expansion will allow consider them as new tools for therapeutic perspectives.

The primary aim of this research was to develop a method for determining the true uniaxial tensile strength of concrete by conducting a series of cylinder splitting, modulus of rupture (MOR) and cylinder/cube compression tests. The main objectives were: • Critically reviewing previous published research in order to identify gaps in current knowledge and understanding, including theoretical and methodological contributions to the true uniaxial tensile strength of concrete. In order to maintain consistency and increase the reliability of the proposed methods, it is essential to review the literature to provide additional data points in order to add additional depth, breathe and rigor to Senussi's investigation (2004). • The design of self compacting concrete (SCC), normal strength concrete (NSC) and high strength concrete (HSC) mixes and undertaking lab-based experimental works for mixing, casting, curing and testing of specimens in order to establish new empirical evidence and data. • Analysing the data, presenting the results, and investigating the application of validity methods as stated by Lin and Raoof (1999) and Senussi (2004). • To draw conclusions including comparison with previous research and literature, including the proposal of new correction factors and recommendations for future research. 29 batches of NSC, 137 batches of HSC, 44 batches of fly ash SCC and 47 batches of GGBS SCC were cast and their hardened and fresh properties were measured. Hardened properties measured included: cylinder splitting strength, MOR, cylinder compressive strength and cube compressive strength. A variety of rheological tests were also applied to characterise the fresh properties of the SCC mixes, including: slump flow, T50, L-box, V-funnel, J-ring and sieve stability. Cylinders were also visually checked after splitting for segregation. The tensile strength of concrete has traditionally been expressed in terms of its compressive strength (e.g. ft = c x c f ). Based on this premise, extensive laboratory testing was conducted to evaluate the tensile strength of the concretes, including the direct tension test and the indirect cylinder splitting and MOR tests. These tests however, do not provide sufficiently accurate results for the true uniaxial tensile strength, due to the results being based upon different test methods. This shortcoming has been overcome by recently developed methods reported by Lin and Raoof (1999) and Senussi (2004) who proposed simple correction factors for the application to the cylinder splitting and MOR test results, with the final outcome providing practically reasonable estimates of the true uniaxial tensile strength of concrete, covering a wide range of concrete compressive strengths 12.57 ≤ fc ≤ 93.82 MPa, as well as a wide range of aggregate types. The current investigation has covered a wide range of ages at testing, from 3 to 91 days. Test data from other sources has also been applied for ages up to 365 days, with the test results reported relating to a variety of mix designs. NSC, SCC and HSC data from the current investigation has shown an encouraging correlation with the previously reported results, hence providing additional wider and deeper empirical evidence for the validity of the recommended correction factors. The results have also demonstrated that the type (size, texture and strength) of aggregate has a negligible effect on the recommended correction factors. The concrete age at testing was demonstrated to have a potentially significant effect on the recommended correction factors. Altering the cement type can also have a significant effect on the hardened properties measured and demonstrated practically noticeable variations on the recommended correction factors. The correction factors proved to be valid regarding the effects of incorporating various blended cements in the HSC and SCC. The NSC, HSC and SCC showed an encouraging correlation with previously reported results, providing additional support, depth, breadth and rigor for the validity of the correction factors recommended.

Diplomová práce se zabývá problematikou volby grafitového materiálu využívaného pro výrobu nástrojových elektrod při elektroerozivní obrábění. Práce je rozdělena do třech částí. Teoretická rešerše nekonvenční technologie elektroerozivního obrábění vypracovaná dle uvedených zdrojů se nachází v první části práce. Dále je v práci proveden cenový průzkum EDM grafitových materiálů nabízených v České republice a na Slovensku. Čtyři odlišné stupně kvality grafitu (od stávajícího dodavatele firmy GAMARTIS TRADE s.r.o.) a jeden měděný materiál byly podrobeny experimentu, jehož účelem bylo zjištění závislosti mezi kvalitou grafitového materiálu (cena) a přesností vyhloubené kavity, opotřebením nástrojové elektrody, časem obrábění nebo také drsností povrchu.

La greffe de cellules souches hématopoïétiques autologue est une thérapie de plus en plus utilisée. Cependant, les traitements de chimiothérapie ou de radiothérapie intensifs peuvent affecter les cellules souches et diminuer le nombre de ces cellules pouvant être mobilisées à des fins de transplantation. Il serait donc très utile de pouvoir expandre ces cellules souches afin de s’assurer qu’elles soient en quantité suffisante pour procéder à la greffe. Or, il a été démontré que la protéine HOXB4 a la capacité d’expandre les cellules souches hématopoïétiques humaines et murines. Lors d’une greffe autologue, la moelle osseuse est cependant colonisée par des cellules malignes. Notre objectif était donc de s’assurer que la protéine HOXB4 expand les cellules souches hématopoïétiques normales mais n’expand pas les cellules « souches » leucémiques. De plus, comme des expériences précédentes ont démontré que chez des souris transplantées avec des cellules souches surexprimant HOXB4, la reconstitution du système hématopoïétique pouvait favoriser les cellules myéloïdes aux dépends des cellules lymphoïdes, nous avons aussi voulu déterminer l’impact de HOXB4 sur la différenciation des cellules progénitrices lymphoïdes normales. Pour ce faire, nous avons exposé des cellules humaines et murines à la protéine HOXB4 afin de comparer la prolifération des cellules B malignes à celle des cellules B normales. De plus, nous avons évalué l’impact de HOXB4 sur les cellules B à leurs différents stades de différenciation. Nos résultats démontrent que HOXB4 ne favorise pas l’expansion des cellules leucémiques. De plus, nous avons observé que les cellules lymphoïdes surexprimant la protéine HOXB4 ont un ralentissement dans leur processus de différenciation. Aussi, la surexpression de HOXB4 entraîne une diminution de la fréquence et du nombre de progéniteurs lymphoïdes normaux. Ces résultats démontrent donc que la protéine HOXB4 ne produit pas d’expansion des cellules malignes. De plus, elle confère un désavantage prolifératif aux cellules lymphoïdes. / Transplantation of autologous hematopoietic stem cell is increasingly used. However, intensive chemotherapy or radiation therapy protocols can affect stem cells and decrease the number of these cells that can be mobilized for stem cell transplantation. There is therefore a need to create protocols for the expansion of these stem cells to increase their numbers sufficiently to proceed to transplantation. It has been demonstrated that the protein HOXB4 has the ability to expand human and murine hematopoietic stem cells. In the context of autologous transplantation, the bone marrow is often colonized by malignant cells. Our objective was to ensure that the protein HOXB4 expands normal hematopoietic stem cells but not leukemia "stem" cells. In addition, since previous experiments have shown that in mice transplanted with stem cells overexpressing HOXB4, hematopoietic reconstitution could favour myeloid cells over lymphoid cells, we determined the impact of HOXB4 on the differentiation of normal lymphoid progenitor cells. Toward this goal, we have exposed human and mouse leukemia cells to HOXB4 and compared the proliferation of malignant versus normal B cells. In addition, we have evaluated the impact of HOXB4 on the different stages of B cell differentiation. Our results show that HOXB4 does not favour leukemia cell expansion. In addition, we observed that lymphoid cells overexpressing HOXB4 are slowed in their differentiation process. Also, HOXB4 overexpression decreases the frequency and number of normal lymphoid progenitors. These results demonstrate that HOXB4 protein does not lead to malignant stem cell expansion. In addition, the HOXB4 protein confers a proliferative disadvantage to lymphoid cells.

Les cellules sanguines proviennent d’une cellule souche hématopoïétique (CSE), présente dans la moelle osseuse chez l’homme adulte, qui nécessite d’être en contact étroit avec une zone particulière du microenvironnement médullaire (appelée niche hématopoïétique) pour sa différenciation et son autorenouvellement. La nature exacte des cellules qui composent cette niche (appelée cellules stromales) n’est pas encore bien connue, en particulier concernant sa relation avec les cellules souches mésenchymateuses (CSM). Le but de cette thèse a été d’étudier le rôle des CSM dans la régulation de l’hématopoïèse en fonction de leur type et leur stade de différenciation mésenchymateuse et d’évaluer leur rôle dans la migration des progéniteurs hématopoïétique (PH). Nous montrons que les CSM non différenciées possèdent la capacité de soutien de l’hématopoïèse primitive la plus importante (par culture à long terme pendant 5 semaines) et que cette capacité est rapidement perdue dès 3 jours de différenciation adipogénique, otéogénique et vasculaire musculaire lisse. Par ailleurs, nous montrons que le G-CSP agit directement sur les CSM pour augmenter la migration des CSH/PH hors de la niche (par un test de migration trans-stromale) via un mécanisme MMP-2 dépendant. / Blood cells arise from a hematopoietic stem cell (HSC), present into bone marrow (3M) in adult humans, which needs close contacts with a special zone of 3M micro environment (named hematopoietic niche) for its differentiation and self’-renewal. The precise nature of the niche-forming cells (named stromale cells) are not yet well known, particularly in their relationship with mesenchymal stem cells (MSCs). The aim of the study was to investigate further the role of the MSCs in the hematopoiesis control according to their differentiation pathway and state and to evaluate their role in the migration process of hematopoietic progenitor cells (HPÇ,[ We show that non-differentiated MSCs display the best hematopoietic supporting activity (using 5-week long term cultures) that is completely lost after in vitro differentiation into adipocytes, osteoblasts and vascular smooth muscle cells. In addition, we show that G-CSP stimulation of 3M MSCs promotes HSC/HPC migration (using trans-stromal migration assay) via a MMP-2-dependent mechanism.

The present study was undertaken to investigate the concerns of secondary school teacher-librarians, that the subject headings set down by the Australian Schools Catalogue Information Service (ASCIS) do not cover topics in senior sourses of study. NSW HSC Economics was chosen to test this perception. Terms were extracted from three textual sources (syllabus, textbook and examination papers) and checked against the subject headings in the ASCIS Subject Headings List. A comparison was made between terms which matched exactly, those which were only partially matched and those which had no match. The linguistic complexity of the term (single-word or multi-word) and the number of textual sources using the term were also taken into account. The results showed a varying degree of match between textual terms and subject headings. Single-word terms found in more than one textual source were much more likely to be found in the subject headings than those from only one textual source. Multi-word terms were found less frequently than single-word terms, but were also more likely to be found when they came from more than one textual source. There was a large number of partial matches in this group, and these were found to be more general in concept than the textual terms. Most of the terms were found, but the general nature of the partial matches and the lack of adequate cross references may cause problems in subject analysis and retrieval.

La greffe de cellules souches hématopoïétiques autologue est une thérapie de plus en plus utilisée. Cependant, les traitements de chimiothérapie ou de radiothérapie intensifs peuvent affecter les cellules souches et diminuer le nombre de ces cellules pouvant être mobilisées à des fins de transplantation. Il serait donc très utile de pouvoir expandre ces cellules souches afin de s’assurer qu’elles soient en quantité suffisante pour procéder à la greffe. Or, il a été démontré que la protéine HOXB4 a la capacité d’expandre les cellules souches hématopoïétiques humaines et murines. Lors d’une greffe autologue, la moelle osseuse est cependant colonisée par des cellules malignes. Notre objectif était donc de s’assurer que la protéine HOXB4 expand les cellules souches hématopoïétiques normales mais n’expand pas les cellules « souches » leucémiques. De plus, comme des expériences précédentes ont démontré que chez des souris transplantées avec des cellules souches surexprimant HOXB4, la reconstitution du système hématopoïétique pouvait favoriser les cellules myéloïdes aux dépends des cellules lymphoïdes, nous avons aussi voulu déterminer l’impact de HOXB4 sur la différenciation des cellules progénitrices lymphoïdes normales. Pour ce faire, nous avons exposé des cellules humaines et murines à la protéine HOXB4 afin de comparer la prolifération des cellules B malignes à celle des cellules B normales. De plus, nous avons évalué l’impact de HOXB4 sur les cellules B à leurs différents stades de différenciation. Nos résultats démontrent que HOXB4 ne favorise pas l’expansion des cellules leucémiques. De plus, nous avons observé que les cellules lymphoïdes surexprimant la protéine HOXB4 ont un ralentissement dans leur processus de différenciation. Aussi, la surexpression de HOXB4 entraîne une diminution de la fréquence et du nombre de progéniteurs lymphoïdes normaux. Ces résultats démontrent donc que la protéine HOXB4 ne produit pas d’expansion des cellules malignes. De plus, elle confère un désavantage prolifératif aux cellules lymphoïdes. / Transplantation of autologous hematopoietic stem cell is increasingly used. However, intensive chemotherapy or radiation therapy protocols can affect stem cells and decrease the number of these cells that can be mobilized for stem cell transplantation. There is therefore a need to create protocols for the expansion of these stem cells to increase their numbers sufficiently to proceed to transplantation. It has been demonstrated that the protein HOXB4 has the ability to expand human and murine hematopoietic stem cells. In the context of autologous transplantation, the bone marrow is often colonized by malignant cells. Our objective was to ensure that the protein HOXB4 expands normal hematopoietic stem cells but not leukemia "stem" cells. In addition, since previous experiments have shown that in mice transplanted with stem cells overexpressing HOXB4, hematopoietic reconstitution could favour myeloid cells over lymphoid cells, we determined the impact of HOXB4 on the differentiation of normal lymphoid progenitor cells. Toward this goal, we have exposed human and mouse leukemia cells to HOXB4 and compared the proliferation of malignant versus normal B cells. In addition, we have evaluated the impact of HOXB4 on the different stages of B cell differentiation. Our results show that HOXB4 does not favour leukemia cell expansion. In addition, we observed that lymphoid cells overexpressing HOXB4 are slowed in their differentiation process. Also, HOXB4 overexpression decreases the frequency and number of normal lymphoid progenitors. These results demonstrate that HOXB4 protein does not lead to malignant stem cell expansion. In addition, the HOXB4 protein confers a proliferative disadvantage to lymphoid cells.

This work concerns malignant myeloid hemopathies called classical BCR-ABL-negative Myeloproliferative Neoplasms (MPN) and include Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). They result from the transformation of a multipotent hematopoietic stem cell (HSC) with hyperproliferation but no blockade of differentiation. The most common molecular defect is the acquired point mutation JAK2V617F resulting into the activation of the cytokine receptor/JAK2 pathway. We have developed a mouse constitutive and a conditional JAK2V617F knock-in (KI) mouse models. These animals developed a disease mimicking human PV evolving into secondary MF. They also displayed an age dependent increase in the total numbers of early hematopoietic cells (phenotype LK, LSK and SLAM: LSK/CD48-/CD150+). Using In vivo competitive repopulation assays we demonstrated that cells from KI origin outcompeted their WT counterparts and that a low number of JAK2V617F KI SLAM cells propagates the disease. These results show that the sole JAK2V617F mutation, without any additional mutations, is sufficient for disease phenotype and emergence. Using this KI mouse model, we tested the effect of interferon-a (IFNa) treatment on MPN development. We found that IFNa treats the disease phenotype by blocking the propagation of early JAK2V617F cells and eradicates disease-initiating cells, showing that IFNα could cure the disease in mice, as shown in some PV patients. Finally, we developed a new method combining the measurement of 46/1 SNPs and JAK2V617F allele burdens in blood predicting the frequency of normal, heterozygous and homozygous JAK2V617F clones in PV patients. This study suggested that IFNa preferentially targets the homozygous JAK2V617F clone in PV patients suggesting a link between the levels of JAK2 signaling and the success of the IFNa response.